Mehmet AKCİCEK, Serkan UNLU, Mehtap ILGAR, Tamer BAYSAL

Comparison of gadoxetic acid and gadobenate dimeglumine, liver-specific contrast agents used in magnetic resonance imaging in differential diagnosis of liver masses

To compare Gadoxetic acid and Gadobenate dimeglumine in the detection and characterization of liver masses. In this study, 59 lesions in 28 patients are included in which were dynamic MRI that had been used Gadoxetic acid (Gd-EOB-DTPA) and Gadobenate dimeglumine (Gd-BOPTA). Observers recorded the liver lesions and adjacent parenchymal signal intensities (SI) in precontrast, arterial and hepatocyte phase by using the ROIs for the quantitative analysis. All statistical analyzes were performed with SPSS 22 software. p

PDF

___

1. Agostini A, Kircher MF, Do R, et al. MR imaging of the liver (including biliary contrast agents): Part 1: technical considerations and Contrast Materials. In: Seminars in roentgenology. NIH Public Access, 2016;p. 308.

2. Lohrke J, Frenzel T, Endrikat J, et al. 25 years of contrast-enhanced MRI: developments, current challenges and future perspectives. Adv Ther. 2016;33:1-28.

3. Karabulut N, Elmas N. Contrast agents used in MR imaging of the liver. Diagn Interv Radiol. 2006;12:22-30.

4. Seale MK, Catalano OA, Saini S, et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;29:1725-48.

5. Gandhi S, Brown M, Wong J, et al. MR Contrast agents for liver imaging: what, when, how. Radio Graphics. 2006;26:1621-36.

6. Namasivayam , Martin DR, Saini S. Imaging of liver metastases: MRI Cancer Imaging. 2007;7:2-9.

7. Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer imaging. 2013;13:567.

8. Park Y, Kim SH, Kim SH, et al. Gadoxetic acid (Gd-EOB-DTPA) – enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol. 2010;11:433-40.

9. Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014;271:426-34.

10. Tamada T, Ito K, Sone T, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging. 2009;29:636-40.

11. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging. 2010;31:356-64.

12. Albiin N. “MRI of focal liver lesions.” Current medical imaging reviews 8.2. 2012;107-16.

13. Morana G, La Torre E, Fuser M, et al. Optimal imaging of focal liver lesions. Imaging in Medicine. 2010;2:497–518.

14. Endrikat J, Schwenke C, Vogtlaender K, et al. Safety profile of gadoxetate disodium in elderly patients (≥ 65 years). Acta Radiologica. 2018;59:81-8.

15. Endrikat JS, Dohanish S, Balzer T, et al. Safety of gadoxetate disodium: results from the clinical phase II–III development program and postmarketing surveillance. J Magn Reson Imaging. 2015;42:634-43.

16. Ringe K, Husarik D, Sirlin C, et al. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR. 2010;195:13-28.

17. Frydrychowicz A, Nagle, SK, D’Souza SL, et al. Optimized high resolution contrast enhanced hepatobiliary imaging at 3 tesla: a cross over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging. 2011;34:585-94.

18. Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci. 2007;6:43-52.

19. Caraiani CN, Dan M, Fenesan DI, et al. Description of focal liver lesions with Gd-EOB-DTPA enhanced MRI. Clujul Med. 2015;88:438.

20. Park G, Kim YK, Kim CS, et al. Diagnostic efficacy of gadoxetic acid - enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol. 2010;83:1010-6.

21. Huppertz A. Gadoxetic acid-enhanced MRI compared with unspecific extracellular contrast media for differential diagnosis of metastasis and benign liver lesions. EJCMO. 2010;1-7.

22. Brismar TB, Dahlström N, Edsborg N, et al. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol. 2009;50:709-15.